Topline data were announced from two phase 3 trials evaluating oveporexton in patients with narcolepsy type 1.

Alkermes ALKS announced positive top-line data from the phase II Vibrance-1 study, which evaluated its novel, investigational ...

A race to develop a new class of drugs could transform treatment for patients with narcolepsy — as well as for patients with ...

Alkermes stock skidded Monday on the back of mixed results for its experimental narcolepsy treatment, an orexin agonist.

Alkermes' alixorexton met key endpoints in a Phase 2 trial for narcolepsy type 1, showing strong efficacy and tolerability ...

Part of a class of therapies that boost “orexin” proteins, the drug just scored positive results in a Phase 2 trial. Analysts have guessed it could ultimately generate billions in sales.

Alkermes outlined plans to move its NT1 drug candidate, alixorexton, into phase 3 after posting results from the midstage ...

Alkermes’ investigational drug helped people with a type of narcolepsy stay awake during the day in a mid-stage trial.

Biotech deals involving assets developed in China are surging, a Jefferies report shows. | Biotech deals involving assets ...

Long term use of once-nightly sodium oxybate is well-tolerated among patients with narcolepsy type 1 or 2 with primarily mild adverse reactions.

Narcolepsy in dogs is pretty rare, but it does happen, especially in certain breeds. It’s a neurological disorder that ...

For example, narcolepsy can be passed between: Parents Siblings Children First-degree relatives of people with narcolepsy and cataplexy actually have a 40 times greater risk of developing the ...